مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

390
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

219
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

COMPARISON OF INTRA-ARTERIAL CHEMOTHERAPY WITH GEMCITABINE OR FLOXURIDINE FOLLOWED BY TACE WITH OXALIPLATINE

Pages

  253-260

Abstract

 Background and Aims: To investigate the efficacy and safety of a GEMCITABINE plus OXALIPLATIN combination regimen and a FLOXURIDINE plus OXALIPLATIN combination regimen used in TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION for patients with inoperable HEPATOCELLULAR CARCINOMA (HCC). Methods: From October 2005 to October 2008, 122 chemonaïve patients with newly diagnosed, inoperable HCC were randomized into a GEMCITABINE plus OXALIPLATIN combination regimen group (GO group) or a FLOXURIDINE plus OXALIPLATIN combination regimen group (FO group). The GO group was treated with 1,600 mg of GEMCITABINE and 200 mg of OXALIPLATIN, and the FO group was treated with 1,000 mg of FLOXURIDINE and 200 mg of OXALIPLATIN. Both groups were treated with glutin and iodolipol as the embolic agent in the TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION (TACE). Results: The progression-free survival, the median survival period, and the median time to progress had no significant difference between the two groups. However, there was a significant difference in the incidence of grade 3/4 thrombocytopenia between the two groups (P = 0.002). Grade 3/4 hematologic toxicity was observed only in the GO group. One patient (1.7%) with grade 3/4 leukopenia and 6 patients (10%) with grade 3/4 thrombocytopenia were observed. A multivariate analysis revealed that the Eastern Cooperative Oncology Group (ECOG) scores and portal vein thrombosis were the only independent prognostic factors that affected progression-free survival. Conclusions: The FLOXURIDINE plus OXALIPLATIN combination regimen was tolerated better than the GEMCITABINE plus OXALIPLATIN combination regimen used in TACE.

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    MING ZHI, H., QIANG, CH., HAI LAN, L., HUI, W., QI ZHONG, CH., JIAN CHENG, L., JIAN XIONG, ZH., & YUN BIN, Y.. (2009). COMPARISON OF INTRA-ARTERIAL CHEMOTHERAPY WITH GEMCITABINE OR FLOXURIDINE FOLLOWED BY TACE WITH OXALIPLATINE. HEPATITIS MONTHLY, 9(4 (25)), 253-260. SID. https://sid.ir/paper/306230/en

    Vancouver: Copy

    MING ZHI H., QIANG CH., HAI LAN L., HUI W., QI ZHONG CH., JIAN CHENG L., JIAN XIONG ZH., YUN BIN Y.. COMPARISON OF INTRA-ARTERIAL CHEMOTHERAPY WITH GEMCITABINE OR FLOXURIDINE FOLLOWED BY TACE WITH OXALIPLATINE. HEPATITIS MONTHLY[Internet]. 2009;9(4 (25)):253-260. Available from: https://sid.ir/paper/306230/en

    IEEE: Copy

    H. MING ZHI, CH. QIANG, L. HAI LAN, W. HUI, CH. QI ZHONG, L. JIAN CHENG, ZH. JIAN XIONG, and Y. YUN BIN, “COMPARISON OF INTRA-ARTERIAL CHEMOTHERAPY WITH GEMCITABINE OR FLOXURIDINE FOLLOWED BY TACE WITH OXALIPLATINE,” HEPATITIS MONTHLY, vol. 9, no. 4 (25), pp. 253–260, 2009, [Online]. Available: https://sid.ir/paper/306230/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button